George Tidmarsh, director of the FDA's Center for Drug Evaluation and Research (CDER), has been appointed as the acting director of the Center for Biologics Evaluation and Research (CBER) following the abrupt resignation of Vinay Prasad. Scott Steele and Brittany Goldberg have been named deputy directors at CBER. Prasad's departure came amid controversy surrounding his decisions on treatments for Duchenne muscular dystrophy and scrutiny related to Sarepta Therapeutics' gene therapy products. Sarepta, a biopharmaceutical company, has faced criticism and regulatory pressure after patient deaths linked to its therapies. Reports indicate Sarepta engaged political consulting and media campaigns targeting FDA officials, including Prasad, contributing to a climate of distrust around the agency's regulatory processes. The situation has raised broader concerns about the FDA's handling of drug approvals and its relationship with pharmaceutical companies.